ARS Pharmaceuticals Posts $72M in Neffy Revenue, Eyes Market Share Expansion
Event summary
- ARS Pharmaceuticals reported $72.2M in U.S. net product revenue from neffy in 2025, its first full year of commercialization.
- The company ended 2025 with $245M in cash, cash equivalents, and short-term investments.
- Neffy is now covered by eight state Medicaid plans without prior authorization, with more expected in 2026.
- ARS Pharma plans to expand its sales force from 106 to 150 in Q2 2026 to increase prescribing depth.
- Phase 2b trial data for neffy in chronic spontaneous urticaria is expected in mid-2026.
The big picture
ARS Pharmaceuticals is positioning neffy as a scalable alternative to traditional epinephrine auto-injectors, leveraging its needle-free design to capture market share. The company's strong cash position and expanding regulatory approvals in key markets like China and Australia underscore its global ambitions. Success will depend on maintaining momentum in U.S. payor negotiations and converting clinical trial data into commercial opportunities.
What we're watching
- Market Penetration
- Whether ARS Pharma can sustain its market share growth as initial prescriptions begin renewing in 2026.
- Regulatory Progress
- The pace at which neffy gains unrestricted access with remaining major payors in the U.S.
- Clinical Expansion
- How Phase 2b data for neffy in chronic spontaneous urticaria could open new market opportunities.
Related topics